Ethical implications of pharmacogenetics--do slippery slope arguments matter?

@article{citeulike:142013, abstract = {Pharmacogenetics is a rapidly expanding area of research exploring the relationship between inter-individual genetic variation and drug response, with the goal of developing genetically optimised therapies. Slippery slope arguments claim that a particular action should be rejected (or supported) because it might be the first step onto a slippery slope leading to undesirable (or desirable) consequences. In this article, several slippery slope arguments relevant to the context of pharmacogenetics are evaluated under consideration of underlying reasons for their popularity. The author concludes that although the examined arguments are unconvincing as slippery slope arguments, they do matter in this context. While positive slippery slope arguments serve as a driving force to fuel the development of pharmacogenetics, their negative counterparts play an important role to sensitise policy makers and the public to potential problems.}, address = {Tuebingen University, Wilhelmstr. 19, 72074 Tuebingen, Germany. lilian.schubert@uni-tuebingen.de}, author = {Schubert, L. }, citeulike-article-id = {142013}, issn = {0269-9702}, journal = {Bioethics}, keywords = {pharmacogenetics}, month = {August}, number = {4}, pages = {361--378}, posted-at = {2005-03-28 17:54:35}, priority = {2}, title = {Ethical implications of pharmacogenetics--do slippery slope arguments matter?}, url = {http://view.ncbi.nlm.nih.gov/pubmed/15449407}, volume = {18}, year = {2004} }

TY - JOUR ID - citeulike:142013 L3 - citeulike-article-id:142013 TI - Ethical implications of pharmacogenetics--do slippery slope arguments matter? JF - Bioethics VL - 18 IS - 4 SP - 361 EP - 378 AD - Tuebingen University, Wilhelmstr. 19, 72074 Tuebingen, Germany. lilian.schubert@uni-tuebingen.de SN - 0269-9702 N2 - Pharmacogenetics is a rapidly expanding area of research exploring the relationship between inter-individual genetic variation and drug response, with the goal of developing genetically optimised therapies. Slippery slope arguments claim that a particular action should be rejected (or supported) because it might be the first step onto a slippery slope leading to undesirable (or desirable) consequences. In this article, several slippery slope arguments relevant to the context of pharmacogenetics are evaluated under consideration of underlying reasons for their popularity. The author concludes that although the examined arguments are unconvincing as slippery slope arguments, they do matter in this context. While positive slippery slope arguments serve as a driving force to fuel the development of pharmacogenetics, their negative counterparts play an important role to sensitise policy makers and the public to potential problems. KW - pharmacogenetics AU - Schubert, L PY - 2004/08// UR - http://view.ncbi.nlm.nih.gov/pubmed/15449407 ER -